T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

Drug prices are up for negotiation on 15 Medicare Part D prescription drugs, including popular weight loss drugs such as Ozempic.

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.